Internal Server Error

About Mammoth View

Mammoth View is a venture capital firm founded in 2002. It is primarily based out of Louisville, United States. It primarily invests in United States based startups. Its investments are spread across a wide range of sectors from Life Sciences to Enterprise Applications and HealthTech. Overall, Mammoth View portfolio has seen 2 IPOs and 17 acquisitions including key companies like Xometry, Apellis Pharmaceuticals and Mersive.
Key Metrics

Mammoth View's List of Top Investments

Mammoth View has a portfolio of 73 companies. Their most notable investments include Xometry and Apellis Pharmaceuticals.Their portfolio spans across United States and Canada. They have invested in Life Sciences, Enterprise Applications, HealthTech and 19 other sectors. Here is the list of top investments by Mammoth View:
Provider of on-demand custom manufacturing platform for prototypes and production parts. The company connects buyers with a network of vetted suppliers offering instant quoting for CNC machining, 3D printing, sheet metal fabrication, injection molding, urethane casting, and metal stamping processes. Its platform supports rapid prototyping through high-volume production with no minimum orders, providing materials like metals, plastics, and composites along with finishing options and assembly services. Digital tools enable file upload, design analysis, project management, and supply chain traceability for startups to enterprises.

Key facts about Xometry

  • Founded Year: 2013
  • Location: Washington, DC (United States)
  • Annual Revenue: $500M - $1B as on Dec 31, 2025
  • Stage: Public
  • Total Funding till date: $200M
  • Employee Count: 1,164 as on Jul 31, 2026
  • Investors: HTIF, ADS Ventures and 20 Others
  • Latest Funding Round: Post IPO, Feb 01, 2022, $*****
  • Highlight: Public
Developer of therapeutics for the treatment of rare diseases. The company is developing transformative therapies for people living with a broad range of debilitating diseases by controlling complement, part of the body’s immune system. The company develops programs across ophthalmology, nephrology, hematology, and neurology.

Key facts about Apellis Pharmaceuticals

  • Founded Year: 2008
  • Location: Crestwood (United States)
  • Annual Revenue: $1B+ as on Dec 31, 2025
  • Last Known Valuation: $*****
  • Stage: Acquired
  • Total Funding till date: $213M
  • Employee Count: 568 as on Jul 31, 2026
  • Investors: Avoro Capital, VenBio and 21 Others
  • Latest Funding Round: Post IPO, May 07, 2020, $*****
  • Highlight: Acquired
Mersive Technologies builds collaboration technology designed for the way people actually work. From wireless content sharing to cloud-managed meeting rooms, Mersive's platforms help IT teams deploy and manage spaces at scale while giving employees and guests a seamless, friction-free experience. With hardware-rooted security and intuitive cloud management platforms, Mersive turns every room into a smarter, more capable space and keeps it that way.

Key facts about Mersive

Developer of therapeutics for the treatment of multiple diseases. The company's drugs include APOKYN (apomorphine hydrochloride injection for Parkinson's disease), CORGARD (nadolol tablets for hypertension, angina pectoris), MYOBLOC (rimabotulinumtoxinB Injection for cervical dystonia), REVONTO (dantrolene sodium injection for anesthetic-induced malignant hyperthermia syndrome) and XADAGO (safinamide tablets for Parkinson's Disease).

Key facts about US World Meds

Provider of solutions for demand response and energy intelligence. It integrates with (IoT)-based devices from third-party device manufacturers and connects to those devices through the device manufacturer's server, using secure server-to-server communication systems. It applies machine learning and real-time control to devices to reduce demand. It offers utilities the power to control demand and also provides data about consumption to the users. Additionally, provides mobile and web applications that can bring together smart device data and billing information to provide a one-stop customer engagement platform.

Key facts about Virtual Peaker

IPOs and Publicly Listed companies in Mammoth View's Portfolio

2 of Mammoth View's portfolio companies have become public. ZYUS Life Sciences got listed on the Toronto Stock Exchange (TSX), in Jun 2023 and Xometry got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ) at marketcap of $1.77B.
Here are Mammoth View's portfolio companies that went public:
Company
IPO Date
First Invested on
First Round of Investment
Round Size
Jun 23, 2023
-
-
2025
Jun 30, 2021
-
-
7200

Acquired companies in Mammoth View's Portfolio

17 companies from Mammoth View's portfolio have been acquired. The most recent acquisition was Apellis Pharmaceuticals in Mar 2026 by Biogen for $*****.
Here are Mammoth View's portfolio companies that got acquired most recently:
Company
Acquisition Date
First Invested on
First Round of Investment
Round Size
Mar 31, 2026
-
-
6193
Dec 20, 2025
-
-
7485
Feb 18, 2025
-
-
8561
Jan 18, 2024
-
-
5409
Nov 02, 2023
-
-
3216

FAQs about Mammoth View

Tracxn powers 1,000+ customers across 30+ countries
Accel PartnersPartechIN-Q-TEL - USFujitsuTenityStanford